Cargando…

Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

Background The entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into type II pneumocytes is dependent on a modification of viral spike proteins by transmembrane protease serine 2 (TMPRSS2) expressed on the surface of human cells. TMPRSS2 is regulated by the androgen receptor, he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cadegiani, Flavio A, McCoy, John, Gustavo Wambier, Carlos, Vaño-Galván, Sergio, Shapiro, Jerry, Tosti, Antonella, Zimerman, Ricardo A, Goren, Andy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Infectious Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899267/ https://www.ncbi.nlm.nih.gov/pubmed/33633920 http://dx.doi.org/10.7759/cureus.13492

Ejemplares similares

Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
por: McCoy, John, et al.
Publicado: (2021)

Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
por: Cadegiani, Flavio A, et al.
Publicado: (2021)

Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine booster
por: Goren, Andy, et al.
Publicado: (2021)

Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial
por: Cadegiani, Flavio A, et al.
Publicado: (2021)

The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1757-Patient Cohort
por: Cadegiani, Flavio A, et al.
Publicado: (2021)

Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign
por: Wambier, Carlos Gustavo, et al.
Publicado: (2020)

Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS)
por: Cadegiani, Flavio A., et al.
Publicado: (2020)

Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19
por: Cadegiani, Flavio A., et al.
Publicado: (2020)

Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients
por: Cadegiani, F.A., et al.
Publicado: (2021)

Reply to comment on: The Gabrin sign
por: Wambier, Carlos Gustavo, et al.
Publicado: (2021)

Male balding as a major risk factor for severe COVID-19: A possible role for targeting androgens and transmembrane protease serine 2 to protect vulnerable individuals
por: Wambier, Carlos Gustavo, et al.
Publicado: (2020)

Stay-At-Home Orders Are Associated With Emergence of Novel SARS-CoV-2 Variants
por: Zimerman, Ricardo A, et al.
Publicado: (2021)

Time of onset and duration of post-COVID-19 acute telogen effluvium
por: Abrantes, Tatiana F., et al.
Publicado: (2021)

Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”
por: Wambier, Carlos Gustavo, et al.
Publicado: (2020)

Comparative Genomics and Characterization of SARS-CoV-2 P.1 (Gamma) Variant of Concern From Amazonas, Brazil
por: Zimerman, Ricardo Ariel, et al.
Publicado: (2022)

SARS-CoV-2 infection in patients with thyroid disease: a cross-sectional study
por: Nguyen, Cristina, et al.
Publicado: (2021)

Retraction: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
Publicado: (2022)

Remission of Severe Myasthenia Gravis After Massive-Dose Vitamin D Treatment
por: Cadegiani, Flávio Adsuara
Publicado: (2016)

Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response
por: Qiao, Yuanyuan, et al.
Publicado: (2023)

Expression of Concern: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
Publicado: (2022)

Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19
por: Bosaeed, Mohammad, et al.
Publicado: (2021)

Acarbose promotes remission of both early and late dumping syndromes in post-bariatric patients
por: Cadegiani, Flavio A, et al.
Publicado: (2016)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated
por: Wambier, Carlos Gustavo, et al.
Publicado: (2020)

Reply to early-onset effluvium secondary to COVID-19 and body hair effluvium
por: Wambier, Carlos Gustavo, et al.
Publicado: (2022)

Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching
por: Kerr, Lucy, et al.
Publicado: (2022)

Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis
por: Gu, Yue, et al.
Publicado: (2021)

Proxalutamide for the treatment of COVID‐19 rebound following Paxlovid treatment: Report of four cases and review of the literature
por: Yang, Da‐Wei, et al.
Publicado: (2023)

Routine Preoperative Dental Clearance for Total Joint Arthroplasty: Is There a Benefit?
por: Kwan, Stephanie A, et al.
Publicado: (2023)

Prevalence of hair shedding among women
por: Kovacevic, Maja, et al.
Publicado: (2016)

The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial
por: Viasus, Diego, et al.
Publicado: (2015)

A randomized, double-blind study on the efficacy of oral domperidone versus placebo for reducing SARS-CoV-2 viral load in mild-to-moderate COVID-19 patients in primary health care
por: Rabanal Basalo, Alejandro, et al.
Publicado: (2023)

Characterization of predictors of ESBL‐producing enterobacteriaceae in urine cultures of emergency department patients
por: Saadi, Raghad, et al.
Publicado: (2021)

Are night shift workers at an increased risk for COVID-19?
por: Lim, Rachel K., et al.
Publicado: (2020)

Augmented Renal Clearance and Hypoalbuminemia-Induced Low Vancomycin Trough Concentrations in Febrile Neutropenic Patients With Hematological Malignancies
por: Alzahrani, Abdullah M, et al.
Publicado: (2022)

Vaccination reduces viral load and accelerates viral clearance in SARS-CoV-2 Delta variant-infected patients
por: Li, Hongxia, et al.
Publicado: (2023)

Coincidence of remission of postpartum Graves' disease and use of omega-3 fatty acid supplements
por: Breese McCoy, Sarah J
Publicado: (2011)

Hydropneumothorax With Persistent Air Leak in a Patient With Mild COVID-19 Disease
por: Pantazopoulos, Ioannis N, et al.
Publicado: (2022)

Artificial intelligence for diagnosis of mild–moderate COVID-19 using haematological markers
por: Chadaga, Krishnaraj, et al.
Publicado: (2023)

Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda
por: Eziefula, Alice Chijioke, et al.
Publicado: (2013)

Chlorhexidine oral rinses for symptomatic COPD: a randomised, blind, placebo-controlled preliminary study
por: Pragman, Alexa A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vv7au57mpaf5pvp3ppgkio8s03